1. 2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts). (September 2015) Authors: Shore, N.; Bailen, J.; Pieczonka, C.; MacLean, D.; Shi, H.; Faessel, H.; Saad, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0226 A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-rising dose study of the btk inhibitor tak-020 in healthy volunteers. (12th June 2018) Authors: Esfandiari, E.; Gevorkyan, H.; Faessel, H.; Zhao, Z.; Hanna, K.; Smithson, G.; Wagner, J.; Fedyk, E. R.; Mclean, L. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 974 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗